B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia

header-info

Apr, 28, 2023

In a cohort of 204 patients with treatment-naïve Waldenström macroglobulinemia randomly administered either 6 cycles of either dexamethasone, rituximab, and cyclophosphamide or bortezomib-dexamethasone, rituximab, and cyclophosphamide, first-line treatment with bortezomib-dexamethasone, rituximab, and cyclophosphamide resulted in increased response rates and safety.

Access the full article to read more here.